The success and failure of BCG - implications for a novel tuberculosis vaccine (Q36191944)

12 August 2017

1 reference

title

The success and failure of BCG - implications for a novel tuberculosis vaccine (English)

1 reference

12 August 2017

0 references

1 reference

Peter Andersen

0 references

T Mark Doherty

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Nature Reviews Microbiology

12 August 2017

published in

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

656-662

1 reference

Correlation between BCG genomics and protective efficacy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Variation in protection by BCG: implications of and for heterologous immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Tuberculosis: distribution, risk factors, mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Comparative Analysis of Different Vaccine Constructs Expressing Defined Antigens fromMycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Boosting vaccine for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Beyond BCG: the potential for a more effective TB vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Tuberculosis vaccine development: recent progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Comparative genomics of the mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Cross-reactions between mycobacteria. II. Crossed immunoelectrophoretic analysis of soluble antigens of BCG and comparison with other mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Naturally attenuated, orally administered Mycobacterium microti as a tuberculosis vaccine is better than subcutaneous Mycobacterium bovis BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Kinetics of delayed-type hypersensitivity to tuberculin induced by bacille Calmette-Guérin vaccination in northern Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Comparative genomics of the leprosy and tubercle bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Prospects for a better vaccine against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Tuberculosis vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Has BCG attenuated to impotence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Does B.C.G. vaccination prevent or postpone the occurrence of tuberculous meningitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

A booster for tuberculosis vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Natural and experimental tuberculosis in monkeys; with observations on immunization and chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

BCG vaccination and tuberculin allergy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

New TB vaccines to be tested

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1211

31 March 2020

Identifiers

DOI

10.1038/NRMICRO1211

1 reference

12 August 2017

1 reference